China-based Everest Medicines (HKG: 1952) has announced that its targeted-release budesonide, Nefecon, has been prescribed for the first time to treat primary immunoglobulin A nephropathy (IgAN) in adults who are at risk of disease progression. This development signifies a significant step forward in the management of IgAN, a condition that affects the kidneys and can lead to severe complications if left untreated.
Exclusive License Agreement with Calliditas
In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas. This agreement grants Everest Medicines the exclusive rights to develop and commercialize Nefecon in Mainland China, Hong Kong, Macau, Taiwan, and Singapore. The partnership with Calliditas underscores Everest Medicines’ commitment to expanding access to innovative treatments for patients across the region.
Implications for IgAN Patients and Healthcare Providers
The first prescription of Nefecon for the treatment of IgAN in adults marks a crucial milestone in providing a targeted therapy option for patients at risk of disease progression. Healthcare providers now have an additional tool to manage IgAN, which can significantly impact the quality of life for those affected by the condition.-Fineline Info & Tech
